IL136142A0 - High drug load immediate and modified release oral dosage formulations and processes for their manufacture - Google Patents

High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Info

Publication number
IL136142A0
IL136142A0 IL13614298A IL13614298A IL136142A0 IL 136142 A0 IL136142 A0 IL 136142A0 IL 13614298 A IL13614298 A IL 13614298A IL 13614298 A IL13614298 A IL 13614298A IL 136142 A0 IL136142 A0 IL 136142A0
Authority
IL
Israel
Prior art keywords
manufacture
processes
oral dosage
modified release
release oral
Prior art date
Application number
IL13614298A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL136142A0 publication Critical patent/IL136142A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13614298A 1997-11-17 1998-11-17 High drug load immediate and modified release oral dosage formulations and processes for their manufacture IL136142A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6591897P 1997-11-17 1997-11-17
PCT/US1998/024502 WO1999025321A1 (en) 1997-11-17 1998-11-17 High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Publications (1)

Publication Number Publication Date
IL136142A0 true IL136142A0 (en) 2001-05-20

Family

ID=22066009

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13614298A IL136142A0 (en) 1997-11-17 1998-11-17 High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Country Status (14)

Country Link
EP (1) EP1033974B1 (xx)
JP (1) JP4880118B2 (xx)
KR (1) KR100597922B1 (xx)
CN (1) CN1285739A (xx)
AU (1) AU750611B2 (xx)
BR (1) BR9814877A (xx)
CA (1) CA2310028C (xx)
HU (1) HUP0004407A3 (xx)
IL (1) IL136142A0 (xx)
NO (1) NO329206B1 (xx)
NZ (1) NZ504565A (xx)
PL (1) PL340587A1 (xx)
TR (1) TR200001412T2 (xx)
WO (1) WO1999025321A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140905A0 (en) * 1998-07-20 2002-02-10 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form
EP1242057A2 (en) 1999-11-02 2002-09-25 DepoMed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0228878D0 (en) * 2002-06-21 2003-01-15 Unilever Plc Hair conditioning composition
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
PT2295035T (pt) * 2007-11-06 2016-08-22 Novartis Ag Composições farmacêuticas de dupla acção com base em superestruturas de antagonista/bloqueador de receptores de angiotensina (arb) com inibidor da endopeptidase neutra (nep)
AR072477A1 (es) * 2008-07-11 2010-09-01 Solvay Pharm Bv Formulacion farmaceutica de eprosartan. uso.
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法
TR201007508A1 (tr) * 2010-09-14 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan bileşimler
CN104546779A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 高药物荷载的枸橼酸西地那非片剂及其制备方法
WO2019072877A1 (en) * 2017-10-10 2019-04-18 Capsugel Belgium Nv GETTING MULTIPARTICULAR COMPOSITIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
CA2168647A1 (en) * 1993-08-02 1995-02-09 Barbara A. Sosnowski Monogenous preparations of cytotoxic conjugates
ES2198564T3 (es) * 1996-03-29 2004-02-01 Smithkline Beecham Corporation Dihidrato de eprosartan y un procedimiento para su produccion y formulacion.

Also Published As

Publication number Publication date
KR100597922B1 (ko) 2006-07-10
KR20010032129A (ko) 2001-04-16
AU1588799A (en) 1999-06-07
CN1285739A (zh) 2001-02-28
NO329206B1 (no) 2010-09-13
EP1033974B1 (en) 2014-01-22
AU750611B2 (en) 2002-07-25
BR9814877A (pt) 2000-10-03
JP2001522872A (ja) 2001-11-20
CA2310028C (en) 2008-06-10
NZ504565A (en) 2002-11-26
CA2310028A1 (en) 1999-05-27
TR200001412T2 (tr) 2000-09-21
WO1999025321A1 (en) 1999-05-27
PL340587A1 (en) 2001-02-12
HUP0004407A3 (en) 2002-03-28
NO20002526D0 (no) 2000-05-16
JP4880118B2 (ja) 2012-02-22
HUP0004407A1 (hu) 2002-02-28
NO20002526L (no) 2000-05-16
EP1033974A1 (en) 2000-09-13
EP1033974A4 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
ZA9811239B (en) Oral pharmaceutical extended release dosage form
EG23875A (en) Oral pharmaceutical pulsed release dosage form
AP9801173A0 (en) Rapidly releasing and taste-making pharmaceutical dosage
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
EP1043030A4 (en) MEDICINAL COMPOSITIONS WITH PROLONGED RELEASE
IL131415A (en) Anti-inflammatory compounds, processes for their preparation and pharmaceutical compositions comprising them
HUP0003526A2 (en) The use of delayed and/or sustained release vitamin d formulations and pharmaceutical compositions containing d-vitamins
EP0858334A4 (en) IMMEDIATE AND SLOW RELEASE ANALGESIC PHARMACEUTICAL COMPOSITION
AU6089200A (en) Rapid immediate release oral dosage form
IL131201A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
HUP0103000A3 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form and process for their preparation
IL136142A0 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
IL145188A0 (en) Processes for making pharmaceutical oral ecb formulations and compositions
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
IL136635A0 (en) Pharmaceutical formulations and processes for their preparation
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
HUP0101012A3 (en) Pharmaceutical composition for oral administration
HUP9902179A3 (en) Pharmaceutical composition comprising immediate release ph-independent solid dosage form of cisapride
SI1043977T1 (en) Oral pharmaceutical pulsed release dosage form
GB9806139D0 (en) Combined aspirin and destrogenic compound pharmaceutical formulation for oral contraception or hormone replacement therapy
IL122719A (en) Controlled release pharmaceutical dosage forms for oral administration containing nifedipine as active substance and process for their preparation
HUP0001584A3 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees